MK-2206 in Recurrent Nasopharyngeal Carcinoma
NCT01370070
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Recurrent Nasopharyngeal Carcinoma
Interventions
DRUG:
MK-2206
Sponsor
Chinese University of Hong Kong